Teligent (NASDAQ:TLGT) announced its earnings results on Friday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.05), MarketWatch Earnings reports. Teligent had a negative net margin of 38.13% and a negative return on equity of 682.10%. The business had revenue of $7.45 million during the quarter.
TLGT traded down $0.01 during trading on Friday, reaching $0.40. The company had a trading volume of 229,008 shares, compared to its average volume of 194,116. Teligent has a 12-month low of $0.19 and a 12-month high of $1.09. The firm’s 50-day simple moving average is $0.37 and its 200 day simple moving average is $0.45. The company has a market cap of $22.09 million, a price-to-earnings ratio of -0.85 and a beta of 2.09.
Separately, ValuEngine upgraded shares of Teligent from a “hold” rating to a “buy” rating in a research report on Friday, March 13th.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.